Last reviewed · How we verify
NCT07119203: STaRLING
Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease
NA trial testing Robotic cholecystectomy in Cholecystectomy, Robotic in 276 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Portsmouth Hospitals NHS Trust |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 276 |
| Start date | 12 September 2025 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Robotic cholecystectomy
- Laparoscopic cholecystectomy
Conditions studied
- Cholecystectomy, Robotic — all drugs for Cholecystectomy, Robotic →
- Cholecystectomy, Laparoscopic — all drugs for Cholecystectomy, Laparoscopic →
- Cholecystectomy — all drugs for Cholecystectomy →
- Gallstones — all drugs for Gallstones →
Sponsor
Portsmouth Hospitals NHS Trust
Who can join
18 and older, any sex, with Cholecystectomy, Robotic or Cholecystectomy, Laparoscopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, randomized controlled, parallel, non-inferiority trial. All adult patients with benign gallbladder disease with an indication for cholecystectomy will be assessed for eligibility and included after obtaining informed consent. A total of 276 patients will be randomized to undergo either robotic cholecystectomy (RC) or laparoscopic cholecystectomy (LC). The primary endpoint will be the incidence and severity of postoperative complications within 30 days after surgery. Secondary endpoints include perioperative outcomes, total health care utilization, health-related quality of life (HR-QoL) as assessed by patient-reported outcome measures, and cost-effectiveness. Follow-up assessments will be conducted at 7 and 30 days postoperatively. This is the first randomized controlled trial designed to compare RC with LC in the treatment of benign gallbladder disease. The trial aims to evaluate the safety and non-inferiority of RC relative to LC, providing important evidence to guide the progress and adoption of robotic surgery in clinical practice.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Surgical Techniques: Robotic versus conventional Laparoscopic cholecystectomy IN benign Gallbladder disease: a randomized controlled, open, parallel, non-inferiority, single-center trial (STaRLING trial).
Straatman J, Kooij CD, Mercer SJ, Pucher PH, et al · · 2026 · PMID 41731509 · DOI 10.1186/s13063-026-09458-0
Verify or expand the search:
- PubMed search for NCT07119203
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Portsmouth Hospitals NHS Trust trials
Trials by the same sponsor.
- NCT07426718 — A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Vol · not yet recruiting
- NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
- NCT07111871 — Healthcare Services for Older People Who Have Fallen With Potential Head Injury · recruiting
- NCT07135960 — Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery) · recruiting
- NCT06351865 — Feasibility Study to Evaluate the Use of Patient Reported Complications After Digital Consent · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07119203 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Portsmouth Hospitals NHS Trust
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07119203.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing